Published in Nat Genet on February 14, 2010
Phenoxybenzamine Versus Doxazosin in PCC Patients (PRESCRIPT) | NCT01379898
Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol (2011) 2.49
Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann Surg Oncol (2013) 2.38
Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas. Arch Pathol Lab Med (2014) 2.31
Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem (2011) 2.24
Global gene disruption in human cells to assign genes to phenotypes by deep sequencing. Nat Biotechnol (2011) 2.23
Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst (2012) 1.78
Digenic inheritance in medical genetics. J Med Genet (2013) 1.38
Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. J Oncol (2012) 1.36
Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genet (2012) 1.34
Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer (2014) 1.33
Tissue-type plasminogen activator regulates the neuronal uptake of glucose in the ischemic brain. J Neurosci (2012) 1.31
New roles of carboxypeptidase E in endocrine and neural function and cancer. Endocr Rev (2012) 1.23
Pheochromocytoma/Paraganglioma: Review of perioperative management of blood pressure and update on genetic mutations associated with pheochromocytoma. J Clin Hypertens (Greenwich) (2013) 1.19
Metastatic paraganglioma. Semin Oncol (2010) 1.12
Familial pediatric endocrine tumors. Oncologist (2011) 1.04
Paragangliomas and paraganglioma syndromes. GMS Curr Top Otorhinolaryngol Head Neck Surg (2012) 1.03
Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors. Horm Metab Res (2013) 0.99
Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction. J Natl Cancer Inst (2013) 0.98
Elevated plasma succinate in PTEN, SDHB, and SDHD mutation-positive individuals. Genet Med (2012) 0.98
Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas. Oncologist (2013) 0.97
Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma. Fam Cancer (2011) 0.94
Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma. Horm Metab Res (2012) 0.94
Pheochromocytoma and paraganglioma in cyanotic congenital heart disease. J Clin Endocrinol Metab (2015) 0.94
Pheochromocytoma: implications in tumorigenesis and the actual management. Minerva Endocrinol (2012) 0.93
Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology (2013) 0.92
Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. J Clin Endocrinol Metab (2010) 0.92
Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options. Curr Opin Endocrinol Diabetes Obes (2013) 0.92
The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma. Endocr Relat Cancer (2012) 0.91
Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors. Front Oncol (2013) 0.91
Management and follow up of extra-adrenal phaeochromocytoma. Cent European J Urol (2014) 0.90
Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. J Mol Endocrinol (2012) 0.90
Hereditary paragangliomas. Adv Otorhinolaryngol (2011) 0.89
Paragangliomas/Pheochromocytomas: clinically oriented genetic testing. Int J Endocrinol (2014) 0.89
Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab (2014) 0.89
Pheochromocytoma - update on disease management. Ther Adv Endocrinol Metab (2012) 0.89
Metastatic pheochromocytoma: does the size and age matter? Eur J Clin Invest (2011) 0.88
Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer (2014) 0.88
Genetic testing for pheochromocytoma. Curr Hypertens Rep (2010) 0.87
An update on the genetics of pheochromocytoma. J Hum Hypertens (2012) 0.87
Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies? Endocr Pathol (2012) 0.87
Adrenal medullary hyperplasia is a precursor lesion for pheochromocytoma in MEN2 syndrome. Neoplasia (2014) 0.87
Subclinical phaeochromocytoma. Best Pract Res Clin Endocrinol Metab (2012) 0.85
The PI3K/Akt Pathway in Tumors of Endocrine Tissues. Front Endocrinol (Lausanne) (2016) 0.85
10 rare tumors that warrant a genetics referral. Fam Cancer (2013) 0.84
The tumor susceptibility gene TMEM127 is mutated in renal cell carcinomas and modulates endolysosomal function. Hum Mol Genet (2013) 0.83
Malignant pheochromocytomas and paragangliomas: a diagnostic challenge. Langenbecks Arch Surg (2011) 0.83
D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2. Nat Commun (2015) 0.83
Acquired hypermethylation of the P16INK4A promoter in abdominal paraganglioma: relation to adverse tumor phenotype and predisposing mutation. Endocr Relat Cancer (2013) 0.83
Rethinking pheochromocytomas and paragangliomas from a genomic perspective. Oncogene (2015) 0.83
The genetic basis of pheochromocytoma and paraganglioma: implications for management. Urology (2014) 0.83
Familial pheochromocytomas and paragangliomas. Mol Cell Endocrinol (2013) 0.83
SDHA related tumorigenesis: a new case series and literature review for variant interpretation and pathogenicity. Mol Genet Genomic Med (2017) 0.82
Prevalence of germline mutations in patients with pheochromocytoma or abdominal paraganglioma and sporadic presentation: a population-based study in Western Sweden. World J Surg (2012) 0.82
Integrative genetic characterization and phenotype correlations in pheochromocytoma and paraganglioma tumours. PLoS One (2014) 0.81
Narrowing the gap of personalized medicine in emerging countries: the case of multiple endocrine neoplasias in Brazil. Clinics (Sao Paulo) (2012) 0.81
Translational research in endocrine surgery. Surg Oncol Clin N Am (2013) 0.81
Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene. Genes Chromosomes Cancer (2015) 0.80
Counseling patients with succinate dehydrogenase subunit defects: genetics, preventive guidelines, and dealing with uncertainty. J Pediatr Endocrinol Metab (2014) 0.80
Phenylethanolamine N-methyltransferase downregulation is associated with malignant pheochromocytoma/paraganglioma. Oncotarget (2016) 0.80
Background gene expression networks significantly enhance drug response prediction by transcriptional profiling. Pharmacogenomics J (2011) 0.80
Role of hypoxia and HIF2α in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features. Adv Pharmacol (2013) 0.80
Progenitor cell line (hPheo1) derived from a human pheochromocytoma tumor. PLoS One (2013) 0.80
Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas. Clin Cancer Res (2015) 0.80
Mitochondrial Deficiencies in the Predisposition to Paraganglioma. Metabolites (2017) 0.79
Copy-number variation is an important contributor to the genetic causality of inherited retinal degenerations. Genet Med (2016) 0.78
Phospho-mTOR is not upregulated in metastatic SDHB paragangliomas. Eur J Clin Invest (2013) 0.78
MAX mutations status in Swedish patients with pheochromocytoma and paraganglioma tumours. Fam Cancer (2014) 0.78
Phenotype of SDHB mutation carriers in the Netherlands. Fam Cancer (2014) 0.78
Genetic screening for von Hippel-Lindau gene mutations in non-syndromic pheochromocytoma: low prevalence and false-positives or misdiagnosis indicate a need for caution. Horm Metab Res (2012) 0.77
A differential diagnosis of inherited endocrine tumors and their tumor counterparts. Clinics (Sao Paulo) (2013) 0.77
Pheochromocytoma and paraganglioma: current functional and future molecular imaging. Front Oncol (2012) 0.77
Integrative analysis of neuroblastoma and pheochromocytoma genomics data. BMC Med Genomics (2012) 0.76
P.Arg82Leu von Hippel-Lindau (VHL) gene mutation among three members of a family with familial bilateral pheochromocytoma in India: molecular analysis and in silico characterization. PLoS One (2013) 0.76
Pheochromocytomas and Paragangliomas: Clinical and Genetic Approaches. Front Endocrinol (Lausanne) (2015) 0.76
Identification of eight novel SDHB, SDHC, SDHD germline variants in Danish pheochromocytoma/paraganglioma patients. Hered Cancer Clin Pract (2016) 0.75
Global DNA Methylation Analysis Identifies Two Discrete clusters of Pheochromocytoma with Distinct Genomic and Genetic Alterations. Sci Rep (2017) 0.75
Novel germline variant of TMEM127 gene in a patient with familial pheochromocytoma. Endocrinol Diabetes Metab Case Rep (2017) 0.75
Bioinformatic Challenges in Clinical Diagnostic Application of Targeted Next Generation Sequencing: Experience from Pheochromocytoma. PLoS One (2015) 0.75
Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127). Endocr Pathol (2017) 0.75
Novel germline SDHD mutation: diagnosis and implications to the patient. Fam Cancer (2011) 0.75
Role of SDHAF2 and SDHD in von Hippel-Lindau associated pheochromocytomas. World J Surg (2014) 0.75
Malignant Pheochromocytoma and Paraganglioma: 272 Patients over 55 Years. J Clin Endocrinol Metab (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 18.22
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science (2008) 14.08
TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell (2006) 7.49
Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med (2002) 6.94
A syntaxin 1, Galpha(o), and N-type calcium channel complex at a presynaptic nerve terminal: analysis by quantitative immunocolocalization. J Neurosci (2004) 4.84
The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell (1990) 4.84
Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet (2006) 4.23
The Vam6 GEF controls TORC1 by activating the EGO complex. Mol Cell (2009) 4.01
Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet (2005) 3.94
The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A (2005) 3.49
Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol (2005) 3.20
A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet (2005) 2.85
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature (2009) 2.77
GOLPH3 bridges phosphatidylinositol-4- phosphate and actomyosin to stretch and shape the Golgi to promote budding. Cell (2009) 2.54
High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer (2007) 2.34
TORC1 is essential for NF1-associated malignancies. Curr Biol (2007) 2.08
PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet (1999) 2.08
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev (2008) 1.93
Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem (2000) 1.47
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood (2004) 1.43
PTPROt: an alternatively spliced and developmentally regulated B-lymphoid phosphatase that promotes G0/G1 arrest. Blood (1999) 1.36
GMx33 associates with the trans-Golgi matrix in a dynamic manner and sorts within tubules exiting the Golgi. Mol Biol Cell (2005) 1.33
Evolving concepts in pheochromocytoma and paraganglioma. Curr Opin Oncol (2006) 1.22
Novel pheochromocytoma susceptibility loci identified by integrative genomics. Cancer Res (2005) 1.01
Asymmetry in the assembly of the RNAi enzyme complex. Cell (2003) 22.18
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med (2002) 14.01
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07
Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA (2004) 4.52
Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab (2005) 4.07
Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet (2006) 3.23
Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA (2005) 2.69
Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A (2010) 2.68
Role of NAD(P)H oxidase- and mitochondria-derived reactive oxygen species in cardioprotection of ischemic reperfusion injury by angiotensin II. Hypertension (2005) 2.67
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Chemical calcium indicators. Methods (2008) 2.33
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet (2011) 2.29
Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn (2013) 2.27
Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol (2005) 2.25
Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol (2009) 2.19
Autophagy regulates the processing of amino terminal huntingtin fragments. Hum Mol Genet (2003) 2.08
Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci U S A (2010) 2.07
Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. Cancer Genet Cytogenet (2008) 2.01
Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamics. Hum Mol Genet (2003) 2.01
MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci U S A (2012) 1.89
Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab (2011) 1.86
Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension (2004) 1.72
Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem (2001) 1.70
Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood (2006) 1.70
Amphetamine-induced dopamine efflux. A voltage-sensitive and intracellular Na+-dependent mechanism. J Biol Chem (2003) 1.69
Altered default mode network connectivity in Alzheimer's disease--a resting functional MRI and Bayesian network study. Hum Brain Mapp (2011) 1.67
PI 3-kinase regulation of dopamine uptake. J Neurochem (2002) 1.64
In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocr Relat Cancer (2013) 1.63
Argonaute protein identity and pairing geometry determine cooperativity in mammalian RNA silencing. RNA (2011) 1.59
Impairment and compensation coexist in amnestic MCI default mode network. Neuroimage (2009) 1.57
The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. PLoS Genet (2009) 1.57
Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest (2011) 1.54
Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/Ca2+/calmodulin-dependent protein kinase kinase-dependent pathways. J Biol Chem (2009) 1.54
Familial mesial temporal lobe epilepsy (FMTLE) : a clinical and genetic study of 15 Italian families. J Neurol (2007) 1.54
Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab (2009) 1.53
Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res (2009) 1.53
Genetic polymorphism of the renin-angiotensin-aldosterone system and arterial hypertension in the Italian population: the GENIPER Project. J Hypertens (2003) 1.52
MicroRNA-155 controls RB phosphorylation in normal and malignant B lymphocytes via the noncanonical TGF-β1/SMAD5 signaling module. Blood (2013) 1.52
Mitochondria-derived reactive oxygen species and vascular MAP kinases: comparison of angiotensin II and diazoxide. Hypertension (2005) 1.47
A case report of successful treatment with plasma exchange for adult-onset Still's disease with autoimmune hepatitis. J Clin Apher (2010) 1.45
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood (2004) 1.43
Phaeochromocytoma, new genes and screening strategies. Clin Endocrinol (Oxf) (2006) 1.41
Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin Cancer Res (2009) 1.38
Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc Res (2005) 1.34
Striatal potassium channel dysfunction in Huntington's disease transgenic mice. J Neurophysiol (2004) 1.30
BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate. Mol Cell Biol (2006) 1.29
Mitochondrial targeted cyclophilin D protects cells from cell death by peptidyl prolyl isomerization. J Biol Chem (2002) 1.29
The BAL-binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activity. J Biol Chem (2003) 1.28
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging (2012) 1.28
Voxel-based assessment of gray and white matter volumes in Alzheimer's disease. Neurosci Lett (2009) 1.27
Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci (2004) 1.27
Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol (2010) 1.26
A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors. Hum Genet (2008) 1.26
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab (2010) 1.24
Matrix metalloproteinase-2 and -9 secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight junction proteins. PLoS One (2011) 1.24
Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease. J Neurosci (2010) 1.23
Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA (2010) 1.22
MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res (2012) 1.22
Huntingtin associates with acidic phospholipids at the plasma membrane. J Biol Chem (2005) 1.22
Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab (2012) 1.21
Effects of AT1 receptor blockade on renal injury and mitogen-activated protein activity in Dahl salt-sensitive rats. Kidney Int (2004) 1.20
Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf) (2007) 1.20
Linking SNPs to CAG repeat length in Huntington's disease patients. Nat Methods (2008) 1.19
Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg (2009) 1.19
Causal interactions in attention networks predict behavioral performance. J Neurosci (2012) 1.18
Is the laparoscopic adrenalectomy for pheochromocytoma the best treatment? Surgery (2007) 1.17
Primary pulmonary malignant melanoma: a clinicopathologic study of two cases. Diagn Pathol (2012) 1.16
Novel redox-dependent regulation of NOX5 by the tyrosine kinase c-Abl. Free Radic Biol Med (2007) 1.16
Activation of the NOTCH pathway in head and neck cancer. Cancer Res (2013) 1.15
Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood (2003) 1.14
Trans-activation of EphA4 and FGF receptors mediated by direct interactions between their cytoplasmic domains. Proc Natl Acad Sci U S A (2005) 1.14
Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. J Clin Endocrinol Metab (2007) 1.13
HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation. Brain (2014) 1.13
Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease. J Cereb Blood Flow Metab (2013) 1.13
Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mutat (2011) 1.12